STOCK TITAN

Vivos Inc - RDGL STOCK NEWS

Welcome to our dedicated news page for Vivos (Ticker: RDGL), a resource for investors and traders seeking the latest updates and insights on Vivos.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vivos's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vivos's position in the market.

Rhea-AI Summary
Vivos Inc. (OTCQB: RDGL) receives Breakthrough Device designation from the FDA for RadioGel Precision Radionuclide Therapy, accelerating the development and review process for potential human clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50.29%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.76%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.3%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.11%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
Vivos Inc

OTC:RDGL

RDGL Rankings

RDGL Stock Data

40.70M
370.51M
5%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Richland

About RDGL

advanced medical isotope corporation (amic) is a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. amic's focus is on transitioning to full operations upon receipt of expected fda clearance for its patented brachytherapy cancer product, yttrium-90 radiogel™. amic intends to file fda premarket notifications for two related yttrium-90 brachytherapy products. brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. annual sales of brachytherapy products exceed $1 billion, about half of which are in the united states. the company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the united states and to enter into licensing arrangements outside of the united states, though the company will evaluate its alternatives before finalizing its plans.